Johnson & Johnson (NYSE:JNJ) Position Trimmed by Fundamentun LLC

Fundamentun LLC decreased its stake in Johnson & Johnson (NYSE:JNJ) by 7.9% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 35,898 shares of the company’s stock after selling 3,065 shares during the quarter. Johnson & Johnson makes up about 1.9% of Fundamentun LLC’s holdings, making the stock its 15th biggest position. Fundamentun LLC’s holdings in Johnson & Johnson were worth $5,900,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. United Capital Management of KS Inc. raised its holdings in Johnson & Johnson by 1.4% in the 1st quarter. United Capital Management of KS Inc. now owns 22,009 shares of the company’s stock worth $3,617,000 after acquiring an additional 296 shares during the period. Boyd Watterson Asset Management LLC OH boosted its position in shares of Johnson & Johnson by 3.6% during the 1st quarter. Boyd Watterson Asset Management LLC OH now owns 19,835 shares of the company’s stock valued at $3,260,000 after acquiring an additional 685 shares in the last quarter. Usca Ria LLC boosted its position in shares of Johnson & Johnson by 17.5% during the 1st quarter. Usca Ria LLC now owns 107,850 shares of the company’s stock valued at $17,725,000 after acquiring an additional 16,039 shares in the last quarter. AE Wealth Management LLC boosted its position in Johnson & Johnson by 5.9% in the first quarter. AE Wealth Management LLC now owns 192,553 shares of the company’s stock valued at $31,646,000 after buying an additional 10,656 shares in the last quarter. Finally, Mosaic Family Wealth LLC boosted its position in Johnson & Johnson by 2.0% in the first quarter. Mosaic Family Wealth LLC now owns 9,387 shares of the company’s stock valued at $1,543,000 after buying an additional 187 shares in the last quarter. Institutional investors and hedge funds own 67.25% of the company’s stock.

NYSE:JNJ opened at $165.21 on Tuesday. Johnson & Johnson has a one year low of $133.65 and a one year high of $173.65. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.24 and a current ratio of 1.48. The stock has a market cap of $434.95 billion, a PE ratio of 25.98, a P/E/G ratio of 3.06 and a beta of 0.70. The stock has a 50 day moving average price of $162.67 and a 200 day moving average price of $156.40.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Monday, April 19th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.34 by $0.25. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The firm had revenue of $22.30 billion during the quarter, compared to analysts’ expectations of $22 billion. During the same quarter last year, the firm earned $2.30 earnings per share. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. As a group, analysts predict that Johnson & Johnson will post 7.99 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 8th. Shareholders of record on Tuesday, May 25th will be paid a dividend of $1.06 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.01. The ex-dividend date is Monday, May 24th. This represents a $4.24 annualized dividend and a yield of 2.57%. Johnson & Johnson’s dividend payout ratio (DPR) is 46.54%.

Several analysts have issued reports on the stock. JPMorgan Chase & Co. upped their price target on shares of Johnson & Johnson from $157.00 to $175.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 27th. Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $178.00 to $187.00 and gave the stock an “overweight” rating in a report on Wednesday, January 27th. Credit Suisse Group boosted their price target on shares of Johnson & Johnson from $168.00 to $193.00 and gave the stock an “outperform” rating in a report on Wednesday, January 27th. Cowen boosted their price objective on Johnson & Johnson from $170.00 to $195.00 and gave the company an “outperform” rating in a research note on Wednesday, January 27th. Finally, Raymond James boosted their price objective on Johnson & Johnson from $158.00 to $183.00 and gave the stock an “outperform” rating in a report on Wednesday, January 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. Johnson & Johnson presently has a consensus rating of “Buy” and an average target price of $182.45.

Johnson & Johnson Profile

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More: FAANG Stocks

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.